Metastatic Breast Cancer Clinical Trials in New York, New York
28 recruitingNew York, New York
Showing 1–20 of 28 trials
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 1
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled284 locationsNCT04862663
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT06246968
Recruiting
Phase 1Phase 2
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06110793
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
LeonaBio500 enrolled224 locationsNCT05696626
Recruiting
Phase 2
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Breast CancerMetastatic Breast CancerMetastatic Breast Carcinoma+3 more
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT05534438
Recruiting
Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+2 more
BriaCell Therapeutics Corporation404 enrolled79 locationsNCT06072612
Recruiting
Phase 1Phase 2
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Metastatic Breast CancerBrain Metastases
Weill Medical College of Cornell University41 enrolled3 locationsNCT03449238
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche792 enrolled45 locationsNCT03424005
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Triple-Negative Breast CancerMetastatic Breast CancerNon-small Cell Lung Cancer+1 more
Memorial Sloan Kettering Cancer Center145 enrolled12 locationsNCT03808337
Recruiting
Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center201 enrolled12 locationsNCT06099769
Recruiting
Phase 2
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+1 more
Memorial Sloan Kettering Cancer Center34 enrolled7 locationsNCT04683679
Recruiting
Not Applicable
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
Metastatic Breast CancerStage IV Breast Cancer AJCC V7
Icahn School of Medicine at Mount Sinai67 enrolled1 locationNCT06405828
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432